2.50
Hdl Handle:
http://hdl.handle.net/10541/76601
Title:
Adjuvant docetaxel for node-positive breast cancer.
Authors:
Martin, Miguel; Pienkowski, Tadeusz; Mackey, John R; Pawlicki, Marek; Guastalla, Jean-Paul; Weaver, Charles; Tomiak, Eva; Al-Tweigeri, Taher; Chap, Linnea; Juhos, Eva; Guevin, Raymond; Howell, Anthony ( 0000-0002-3879-5991 ) ; Fornander, Tommy; Hainsworth, John; Coleman, Robert E; Vinholes, Jefferson; Modiano, Manuel; Pinter, Tamas; Tang, Shou C; Colwell, Bruce; Prady, Catherine; Provencher, Louise; Walde, David; Rodriguez-Lescure, Alvaro; Hugh, Judith; Loret, Camille; Rupin, Matthieu; Blitz, Sandra; Jacobs, Philip; Murawsky, Michael; Riva, Alessandro; Vogel, Charles L
Abstract:
BACKGROUND: We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS: We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS: At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P<0.001); rates of febrile neutropenia were 24.7 percent and 2.5 percent, respectively (P<0.001). Grade 3 or 4 infections occurred in 3.9 percent of the patients who received TAC and 2.2 percent of those who received FAC (P=0.05); no deaths occurred as a result of infection. Two patients in each group died during treatment. Congestive heart failure and acute myeloid leukemia occurred in less than 2 percent of the patients in each group. Quality-of-life scores decreased during chemotherapy but returned to baseline levels after treatment. CONCLUSIONS: Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.
Affiliation:
Hospital Universitario San Carlos, Madrid, Spain. mmartin@geicam.org
Citation:
Adjuvant docetaxel for node-positive breast cancer. 2005, 352 (22):2302-13 N. Engl. J. Med.
Journal:
The New England Journal of Medicine
Issue Date:
2-Jun-2005
URI:
http://hdl.handle.net/10541/76601
DOI:
10.1056/NEJMoa043681
PubMed ID:
15930421
Type:
Article
Language:
en
ISSN:
1533-4406
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMartin, Miguel-
dc.contributor.authorPienkowski, Tadeusz-
dc.contributor.authorMackey, John R-
dc.contributor.authorPawlicki, Marek-
dc.contributor.authorGuastalla, Jean-Paul-
dc.contributor.authorWeaver, Charles-
dc.contributor.authorTomiak, Eva-
dc.contributor.authorAl-Tweigeri, Taher-
dc.contributor.authorChap, Linnea-
dc.contributor.authorJuhos, Eva-
dc.contributor.authorGuevin, Raymond-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorFornander, Tommy-
dc.contributor.authorHainsworth, John-
dc.contributor.authorColeman, Robert E-
dc.contributor.authorVinholes, Jefferson-
dc.contributor.authorModiano, Manuel-
dc.contributor.authorPinter, Tamas-
dc.contributor.authorTang, Shou C-
dc.contributor.authorColwell, Bruce-
dc.contributor.authorPrady, Catherine-
dc.contributor.authorProvencher, Louise-
dc.contributor.authorWalde, David-
dc.contributor.authorRodriguez-Lescure, Alvaro-
dc.contributor.authorHugh, Judith-
dc.contributor.authorLoret, Camille-
dc.contributor.authorRupin, Matthieu-
dc.contributor.authorBlitz, Sandra-
dc.contributor.authorJacobs, Philip-
dc.contributor.authorMurawsky, Michael-
dc.contributor.authorRiva, Alessandro-
dc.contributor.authorVogel, Charles L-
dc.date.accessioned2009-08-06T15:41:38Z-
dc.date.available2009-08-06T15:41:38Z-
dc.date.issued2005-06-02-
dc.identifier.citationAdjuvant docetaxel for node-positive breast cancer. 2005, 352 (22):2302-13 N. Engl. J. Med.en
dc.identifier.issn1533-4406-
dc.identifier.pmid15930421-
dc.identifier.doi10.1056/NEJMoa043681-
dc.identifier.urihttp://hdl.handle.net/10541/76601-
dc.description.abstractBACKGROUND: We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS: We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS: At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P<0.001); rates of febrile neutropenia were 24.7 percent and 2.5 percent, respectively (P<0.001). Grade 3 or 4 infections occurred in 3.9 percent of the patients who received TAC and 2.2 percent of those who received FAC (P=0.05); no deaths occurred as a result of infection. Two patients in each group died during treatment. Congestive heart failure and acute myeloid leukemia occurred in less than 2 percent of the patients in each group. Quality-of-life scores decreased during chemotherapy but returned to baseline levels after treatment. CONCLUSIONS: Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshCyclophosphamide-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDoxorubicin-
dc.subject.meshFemale-
dc.subject.meshFluorouracil-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshLymphatic Metastasis-
dc.subject.meshMiddle Aged-
dc.subject.meshQuality of Life-
dc.subject.meshSurvival Analysis-
dc.subject.meshTaxoids-
dc.titleAdjuvant docetaxel for node-positive breast cancer.en
dc.typeArticleen
dc.contributor.departmentHospital Universitario San Carlos, Madrid, Spain. mmartin@geicam.orgen
dc.identifier.journalThe New England Journal of Medicineen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.